News

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2024.

Highlights and Outlook

• 
  Q2 sales grew 7%; constant currency¹ sales grew 8%
  


• 
  Q2 TAVR

CenterWell, the health care services business of Humana Inc. (NYSE: HUM), today announced plans to lease clinical space and open senior-focused primary care centers at 23 Walmart Supercenter retail

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene therapy for the

Leading health and well-being company Humana Inc. (NYSE: HUM), through its payor-agnostic insurance brokerage business, today announced a minority investment in Healthpilot, a company pioneering

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2024 after the market closes on Wednesday, July 24, 2024, and will host a conference call at

Agilent Technologies Inc. (NYSE: A) will release financial results for the third quarter of fiscal year 2024 after the stock market closes on Aug. 21. In addition, the company will host a

Humana Inc. (NYSE: HUM) scored 100 on the Disability Equality Index® for the fifth consecutive year, demonstrating the company’s continued commitment to building and maintaining a culture of

Pfizer Inc. (NYSE: PFE) today announced that based on results from the ongoing pharmacokinetic study (NCT06153758), the company has selected its preferred once-daily modified release formulation

Pfizer Inc. (NYSE: PFE) today announced that the company is launching the process to identify a successor for Dr. Mikael Dolsten, Pfizer’s Chief Scientific Officer and President, Pfizer Research &amp

Pfizer Inc. (NYSE: PFE) today announced the election of Cyrus Taraporevala to its Board of Directors, effective immediately. Mr. Taraporevala, age 57, was also appointed to and will join the Audit

Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 third-quarter 2024 dividend on the company’s common stock, payable September 3, 2024, to holders of the Common

DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced that people living with Type 1 diabetes in the Netherlands will be

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM use among people with Type

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EDT on Tuesday, July 30, 2024. The

Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in patients with heavily pretreated relapsed or

Pfizer Inc. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy